- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Chinese authority suspends import, sale, and use of Dr Reddy's Labs Atomoxetine Hydrochloride Capsules
![Chinese authority suspends import, sale, and use of Dr Reddys Labs Atomoxetine Hydrochloride Capsules Chinese authority suspends import, sale, and use of Dr Reddys Labs Atomoxetine Hydrochloride Capsules](https://medicaldialogues.in/h-upload/2024/01/20/750x450_230651-dr-reddys-new-50.webp)
Through a recent BSE filing, Dr Reddy's Labs has informed that the National Medical Products Administration, China (NMPA) has suspended the import, sale, and use of the Company's Atomoxetine Hydrochloride Capsules.
NMPA China recently conducted a remote inspection of the Company’s formulations manufacturing facility (FTO-3) for Atomoxetine Hydrochloride Capsules, and concluded that the production quality management of Atomoxetine Hydrochloride Capsules does not meet the requirements of China's "Good Manufacturing Practice for Drugs (Revised in 2010)".
Atomoxetine Hydrochloride Capsules is a medication used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children and adults.
Further, National Drug Joint Procurement Office, China (NDJPO), having considered the said order of the NMPA, has decided to cancel Dr. Reddy's Laboratories Ltd.'s Atomoxetine Hydrochloride Capsules “won” status and list the company on the "Violation List", suspending the company's eligibility to participate in China'snational centralized drug procurement activities from August 30, 2024 to February 28, 2026.
Both NMPA and NDJPO orders are dated August 30, 2024.
"The Company is in the process of ascertaining the monetary impact of the said orders," Dr Reddy's Labs stated.
Read also: Dr Reddy's Labs gets 3 USFDA observations for Srikakulam facility
Established in 1984, Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. The Company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
Dr Reddy's Labs major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe.
Read also: Dr Reddy's Labs gets USFDA EIR for Duvvada formulations manufacturing facilities
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751